Startseite>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>Pomalidomide-amido-C1-Br

Pomalidomide-amido-C1-Br

Katalog-Nr.GC39171

Pomalidomid-amido-C1-Br ist ein synthetisiertes E3-Ligase-Ligand-Linker-Konjugat, das den auf Pomalidomid basierenden Cereblon-Liganden und einen Linker enthÄlt. Pomalidomid-amido-C1-Br kann verwendet werden, um einen B-Raf-PROTAC-Degrader PROTAC B-Raf-Degrader 1 zu entwickeln. PROTAC B-Raf-Degrader 1 hat AntikrebsaktivitÄt.

Products are for research use only. Not for human use. We do not sell to patients.

Pomalidomide-amido-C1-Br Chemische Struktur

Cas No.: 2351106-38-0

Größe Preis Lagerbestand Menge
5mg
181,00 $
Auf Lager
10mg
285,00 $
Auf Lager
50mg
855,00 $
Auf Lager
100mg
1.215,00 $
Auf Lager
200mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pomalidomide-amido-C1-Br is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker. Pomalidomide-amido-C1-Br can be used to design a B-Raf PROTAC degrader PROTAC B-Raf degrader 1. PROTAC B-Raf degrader 1 has anti-cancer activity[1].

[1]. Chen H, et al. Pomalidomide hybrids act as proteolysis targeting chimeras: Synthesis, anticancer activity and B-Raf degradation. Bioorg Chem. 2019 Jun;87:191-199.

Bewertungen

Review for Pomalidomide-amido-C1-Br

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pomalidomide-amido-C1-Br

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.